Transvaginal Mesh Lawsuit Settlement Announced for Some American Medical Systems Cases, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) October 01, 2014 -- Endo International Plc. has reached transvaginal mesh lawsuit (http://www.drugbot.com/transvaginal-mesh/lawsuit/) settlements in thousands of cases filed against its American Medical Systems, Inc. subsidiary, Bernstein Liebhard LLP reports. According to Reuters, the company has not admitted to any liability in resolving the lawsuits, and has stated that it will increase funds it had set aside to cover vaginal mesh claims from $1.2 billion to approximately $1.6 billion.*
“Our Firm is representing hundreds of women who were allegedly harmed by vaginal mesh devices marketed by American Medical Systems and others. We are pleased to see these cases moving forward, and will be reviewing this settlement agreement closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate transvaginal mesh lawsuits on behalf of women who suffered mesh erosion, chronic pain, and organ damage, allegedly due to devices marketed by American Medical Systems, as well as Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Vaginal Mesh Litigation
According to court documents, American Medical Systems is named a defendant in more than 20,000 transvaginal mesh lawsuits, the majority of which are pending in a multidistrict litigation underway in U.S. District Court, Southern District of West Virginia. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is a member of the Plaintiffs’ Steering Committee for this proceeding. All of the claims involving American Medical Systems allege that its surgical mesh products used to treat pelvic organ prolapse and stress urinary incontinence were defectively designed and caused recipients to suffer serious vaginal mesh complications, including mesh erosion, chronic pain and organ damage. (In Re American Medical Systems, Inc. - MDL No. 2325)
The litigation involving vaginal mesh has been growing since October 2008, when the U.S. Food & Drug Administration (FDA) first alerted the public to the serious risk of vaginal mesh complications associated with these products. In July 2011, the agency issued a second alert after it received thousands of additional reports of injuries associated with these devices. In January 2012, the FDA ordered transvaginal mesh manufacturers to conduct postmarket surveillance studies, such as the one being conducted by American Medical Systems, to address specific safety and effectiveness concerns related to the use of transvaginal mesh in prolapse repair. Finally, this past April FDA announced a proposal that would reclassify mesh products used to treat prolapse as high-risk medical devices.
Court records indicate that more than 60,000 product liability claims have been filed in U.S. courts against the manufacturers of transvaginal mesh products. In addition to his work on the federal proceeding for cases involving American Medical Systems, Mr. Grand is also serving on the Plaintiffs’ Steering Committees for several other vagina mesh litigations underway in the Southern District of West Virginia, including Boston Scientific Corp., (MDL 2326), C.R. Bard, Inc. (MDL 2325) and Ethicon, Inc. (MDL No. 2327).
Mr. Grand is also serving as Co-Liaison Counsel in two consolidated proceedings established for C.R. Bard and Ethicon mesh lawsuits in New Jersey's Atlantic Superior Court. He was also a member of the plaintiff’s trial team for the first Ethicon trial, which ended in March 2013 with an $11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10).
Alleged victims of serious vaginal mesh complications may be entitled to compensation for their injury-related damages. To learn more about filing a transvaginal mesh lawsuit, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
*reuters.com/article/2014/09/30/endo-mesh-settlement-idUSL2N0RV37020140930, Reuters, September 30, 2014
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.drugbot.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, DrugBot.com, http://www.drugbot.com/, +1 800-511-5092, [email protected]
Share this article